- Entry into the Veterans Health Administration (VHA) medical system, the largest in North America
- Targeting the 4.7 trillion KRW (approx. $3.5 billion) VA diabetic foot market... Tackling federal procurement through 'amputation prevention' and 'medical cost reduction'
- Full-scale corporate revaluation and global "quantum jump" expected upon adoption as U.S. Standard of Care (SOC)

ROKIT Healthcare (KOSDAQ 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, has made a decisive entry into the federal Veterans Affairs medical system, beginning the supply of its diabetic foot ulcer (DFU) and skin regeneration platforms to general hospitals under the Veterans Health Administration (VHA).

Having validated its technological prowess through Northwell Health, New York's largest private healthcare network, ROKIT Healthcare has successfully established a path to expand its private-sector references into public (veterans) channels by entering the VHA supply system. This signifies that ROKIT Healthcare's AI organ regeneration platform has entered a trajectory of full-scale growth and commercialization in the U.S. market.

Targeting an Annual $3.5 Billion (4.7 Trillion KRW) VA Diabetes Market… Proving Clinical Efficiency

VHA is the largest integrated healthcare system in the U.S., with over 9.2 million registered patients and an annual medical budget exceeding $120 billion (approx. 162 trillion KRW) as of this year. Notably, annual spending on diabetes-related treatments within the VHA reaches approximately $3.5 billion (4.7 trillion KRW), positioning ROKIT Healthcare’s solution as a key model for enhancing the fiscal efficiency of veteran healthcare.

Based on this VHA supply reference, ROKIT Healthcare plans to accelerate its entry into the broader U.S. public insurance market. Industry insiders predict that this entry will serve as a bridgehead for inclusion in the U.S. Standard of Care (SOC) guidelines, driving a qualitative revaluation of the company's value.

An industry official commented, "Entering the VHA signifies official recognition of our technology within the U.S. medical system. It is expected to be a powerful stepping stone for future expansion into Medicare and Medicaid. Furthermore, listing as a Standard of Care (SOC) could become a catalyst for rapidly expanding market share in the global medical market."

Upward Trend Based on Performance… Solidifying Global Leadership in Organ Regeneration

ROKIT Healthcare has strengthened market trust by demonstrating exceptional revenue growth and achieving an annual operating profit surplus in 2025. Joining the U.S. federal government supply chain is expected to be a decisive turning point for driving qualitative growth and expanding market share in the global public healthcare sector.

A ROKIT Healthcare representative stated, "This entry into the U.S. Veterans Affairs medical system will serve as a vital opportunity to elevate our corporate value. We will continue to solidify our position as the world's leading organ regeneration platform company."